A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Mumpsvax Side Effects, and Drug Interactions - Mumps Virus Vaccine Live
Mumpsvax Side Effects, and Drug Interactions - Mumps Virus Vaccine Live
SIDE EFFECTS
The following adverse reactions are listed in decreasing order of severity,
without regard to causality, within each body system category and have
been reported during clinical trials, with use of the marketed vaccine,
or with use of polyvalent vaccine containing mumps:
Body as a Whole: Fever; syncope; irritability.
Cardiovascular System: Vasculitis.
Digestive System: Pancreatitis; diarrhea; parotitis.
Endocrine System: Diabetes mellitus.
Hemic and Lymphatic System: Thrombocytopenia; purpura;
lymphadenopathy; leukocytosis.
Immune System: Anaphylaxis and anaphylactoid reactions
have been reported as well as related phenomena such as angioneurotic
edema (including peripheral or facial edema) and bronchial spasm.
Nervous System: Encephalitis; Guillain-Barré Syndrome (GBS);
febrile seizures; ocular palsies.
Cases of aseptic meningitis have been reported to VAERS following measles,
mumps, and rubella vaccination. Although a causal relationship between
the Urabe strain of mumps vaccine and aseptic meningitis has been shown,
there are no data to link Jeryl Lynn mumps vaccine to aseptic meningitis.
Respiratory System: Cough; rhinitis.
Skin: Stevens-Johnson Syndrome; erythema multiforme; urticaria.
Local reactions including burning/stinging at injection site; wheal and
flare.
Special Senses — Ear: Nerve deafness; otitis media.
Special Senses — Eye: Optic neuritis; papillitis; retrobulbar
neuritis; conjunctivitis.
Urogenital System: Orchitis.
Other: Death from various, and in some cases unknown, causes
has been reported rarely following vaccination with measles, mumps, and
rubella vaccines; however, a causal relationship has not been established.
No deaths or permanent sequelae were reported in a published post-marketing
surveillance study in Finland involving 1.5 million children and adults
who were vaccinated with M-M-R II during 1982-1993.33
Under the National Childhood Vaccine Injury Act of 1986, health-care
providers and manufacturers are required to record and report certain
suspected adverse events occurring within specific time periods after
vaccination. However, the U. S. Department of Health and Human Services
(DHHS) has established a Vaccine Adverse Event Reporting System (VAERS)
which will accept all reports of suspected events.32 A VAERS
report form as well as information regarding reporting requirements can
be obtained by calling VAERS 1-800-822-7967.
DRUG INTERACTIONS
See DOSAGE AND ADMINISTRATION: Use
With Other Vaccines.
Immunosuppressive Therapy
The immune status of patients about to undergo immunosuppressive therapy
should be evaluated so that the physician can consider whether vaccination
prior to the initiation of treatment is indicated (see CONTRAINDICATIONS
and PRECAUTIONS).
The ACIP has indicated that patients with leukemia in remission who have
not received chemotherapy for at least 3 months may receive live virus
vaccines. Short-term (< 2 weeks), low-to moderate-dose systemic corticosteroid
therapy, topical steroid therapy (e. g., nasal, skin), long-term alternate-day
treatment with low to moderate doses of short-acting systemic steroid,
and intra-articular, bursal, or tendon injection of corticosteroids are
not immunosuppressive in their usual doses and do not contraindicate the
administration of mumps vaccine.16
Immune Globulin
Administration of immune globulins concurrently with MUMPSVAX may interfere
with the expected immune response.16,29
See also PRECAUTIONS: General.
top
